Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13177704 | 0.79 | MMP12 (0.39) | GAAALDH1A1KDM4ESMN1; SMN2AKR1B1 | |
| SCHEMBL4325624 | 0.78 | AHR (0.38) | GAAALDH1A1MAPTLMNAAKR1B1 | |
| SCHEMBL10061004 | 0.75 | PARP1 (0.43) | GAAALDH1A1KDM4ENPC1MAPT | |
| SCHEMBL6125096 | 0.75 | ALDH1A1 (0.34) | ALDH1A1NPC1MAPTHPGDCASP3 | |
| SCHEMBL632647 | 0.73 | PDK2 (0.37) | GAAALDH1A1KDM4E | |
| SCHEMBL1951724 | 0.72 | ALDH1A1 (0.47) | PDE7AGAAALDH1A1KDM4EMAPT | |
| SCHEMBL4838946 | 0.69 | ALDH1A1 (0.51) | PDE7AGAAALDH1A1KDM4EMAPT | |
| SCHEMBL3626752 | 0.67 | PDE3B (0.49) | ALDH1A1KDM4ENPC1MAPTHPGD | |
| SCHEMBL3378790 | 0.67 | PGR (0.72) | PDE7APGR | |
| SCHEMBL5908054 | 0.65 | SNCA (0.41) | PDE7AALDH1A1KDM4EMAPTCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1901776-B1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | BOEHRINGER INGELHEIM INT (DE) | 2012-02-22 | — | — | EP | disclosed |
| EP-1911749-B1 | New long-working Beta-2 agonists and their use as medicine | BOEHRINGER INGELHEIM INT (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-7632834-B2 | Long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-15 | — | — | US | disclosed |
| US-20080194550-A1 | LONG ACTING BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | BOUYSSOU THIERRY | 2008-08-14 | — | — | US | disclosed |
| US-7375104-B2 | Long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| EP-1911749-A1 | New long-working Beta-2 agonists and their use as medicine | Boehringer Ingelheim International GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1901776-A1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | Boehringer Ingelheim International GmbH (DE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1711480-B1 | NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-20070066609-A1 | Long acting beta-2-agonists and their use as medicaments | BOUYSSOU THIERRY | 2007-03-22 | — | — | US | disclosed |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2007003554-A1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE. | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
| US-7160882-B2 | Long acting β-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-09 | — | — | US | disclosed |
| EP-1711480-A1 | NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-10-18 | — | — | EP | disclosed |
| US-20050227975-A1 | New long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| WO-2005070908-A1 | NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066609-A1 | Long acting beta-2-agonists and their use as medicaments | ADRB2, ADRB1, CHRM1 | PDE7A 1270/4885GAA 4176/4885ALDH1A1 1450/4885 |
| US-20050227975-A1 | New long acting beta-2-agonists and their use as medicaments | ADRB2, ADRA2A, ADRB1 | PDE7A 947/4885GAA 3786/4885ALDH1A1 1311/4885 |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | ADRB2, ADRA2A, ADRB1 | PDE7A 1178/4885GAA 628/4885ALDH1A1 1413/4885 |
| US-20080194550-A1 | LONG ACTING BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | ADRB2, ADRB1, CHRM1 | PDE7A 1259/4885GAA 4186/4885ALDH1A1 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.